Growth N. V. Biotech Purchases 60,000 Shares of Radius Health, Inc. (RDUS) Stock
Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 60,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average price of $35.98 per share, with a total value of $2,158,800.00. Following the completion of the purchase, the insider now owns 5,248,799 shares of the company’s stock, valued at $188,851,788.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Radius Health, Inc. (NASDAQ RDUS) opened at 35.52 on Friday. The stock’s 50 day moving average price is $41.97 and its 200 day moving average price is $40.13. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $59.22. The company’s market capitalization is $1.55 billion.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.23. The firm had revenue of $0.98 million during the quarter, compared to the consensus estimate of $1.96 million. During the same period in the previous year, the company posted ($1.01) earnings per share. Analysts anticipate that Radius Health, Inc. will post ($5.51) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/20/growth-n-v-biotech-purchases-60000-shares-of-radius-health-inc-rdus-stock.html.
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after buying an additional 2,628,070 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after buying an additional 569,300 shares during the period. TimesSquare Capital Management LLC purchased a new position in shares of Radius Health during the second quarter valued at $25,589,000. BB Biotech AG raised its position in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after buying an additional 498,400 shares during the period. Finally, RA Capital Management LLC purchased a new position in shares of Radius Health during the second quarter valued at $22,486,000. 97.66% of the stock is owned by institutional investors.
RDUS has been the subject of several research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $65.00 target price on shares of Radius Health in a research note on Friday, April 28th. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, May 4th. Canaccord Genuity reiterated a “buy” rating on shares of Radius Health in a research note on Friday, April 28th. HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Radius Health in a research note on Monday, May 15th. Finally, Maxim Group reiterated a “sell” rating on shares of Radius Health in a research note on Monday, May 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $53.60.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.